ROMAZA: Phase I study of Romidespin and Azacitidine in AML patients

• Research type

  Research Study

• Full title

  ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy

• IRAS ID

  101937

• Contact name

  Charles Craddock

• Contact email

  Charles.Craddock@uhb.nhs.uk

• Sponsor organisation

  University of Birmingham

• Eudract number

  2011-005023-40

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  13/SC/0157

• Date of REC Opinion

  8 May 2013

• REC opinion

  Further Information Favourable Opinion